Allergy and Asthma

Main Content

ANDHI

Study title

Multicenter, randomized, double blind, phase 3b study to evaluate the safety and efficacy of Benralizumab 30 mg sc in patients with severe asthma uncontrolled on standard of care treatment.

  • Principal Investigator: Gailen Marshall, MD PhD

Purpose

This study is looking at an investigational medication to see how safe it is and how well it works to treat the symptoms of severe and uncontrolled asthma.

Who can participate

Those eligible to participate in this study include:

  • Adults ages 18-75 who have had 2 or more asthma attacks in the past 12 months, despite using regular asthma medication

For more information

  • Megan Horne
    University of Mississippi Medical Center
    2500 N. State St. 
    Jackson, MS 39216
    (601) 815-5527
  • IRB Number: 2017-0223